Available via license: CC BY 4.0
Content may be subject to copyright.
pharmaceutics
Editorial
Clay-Based Pharmaceutical Formulations and Drug
Delivery Systems
Fátima García-Villén1and César Viseras 1, 2, *
1Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Granada,
Campus of Cartuja, 18071 Granada, Spain; fgarvillen@ugr.es
2
Andalusian Institute of Earth Sciences, CSIC-UGR, Avenida de las Palmeras 4, 18100 Armilla, Granada, Spain
*Correspondence: cviseras@ugr.es
Received: 19 November 2020; Accepted: 24 November 2020; Published: 25 November 2020
The use of minerals as ingredients in health care products is a classical and active pharmaceutical
subject. Clays and also zeolites and other silica-based mesoporous inorganic ingredients have been
traditionally used as pharmaceutical and cosmetic ingredients. These inorganic ingredients should
meet the quality and safety standards to be used as ingredients in health care products. Recently,
new and advanced applications of these materials have been proposed, including the design of
modified drug delivery systems and other advanced applications (such as wound healing formulations
and tissue engineering scaffolds).
This Special Issue highlights the most relevant and recent advances in clay-based formulations
and clay-based drug delivery systems. Natural, modified, and synthetic clays with prospects in
nanomedicine and pharmaceutics were considered.
The publication of Maestrelli et al. [
1
] used a combination of cyclodextrins and nanoclays to improve
the biopharmaceutical profile of hydrochlorothiazide, characterized by low solubility and permeability.
Once the best cyclodextrin (RAMEB) and clay (sepiolite) were selected, the co-evaporation technique
was used to prepare a ternary system with an optimal drug:carrier ratio. The combined presence
of RAMEB and sepiolite gave rise to a synergistic improvement in the drug dissolution properties,
resulting in an approximately 12-fold increase in the hydrochlorothiazide solubility compared with
the drug alone. Subsequently, the ternary system was formulated as tablets and a full technological
characterization was performed. The results clearly revealed a better drug dissolution performance
than the commercial hydrochlorothiazide reference tablet (Esidrex®).
The publication by Borrego-S
á
nchez et al. [
2
] studied the interaction between praziquantel, the drug
indicated for schistosomiasis disease, and two clays (sepiolite and montmorillonite). Praziquantel has
a very low aqueous solubility, requiring high oral doses, which usually lead to side effects, therapeutic
noncompliance, and the appearance of resistant forms of the parasite. The drug was dissolved in
organic solvents (ethanol, acetonitrile, and dichloromethane) and encapsulated in nanometric channels
of sepiolite or between the layers of montmorillonite. The results showed that the interaction of
the drug with both clay minerals produced a loss of praziquantel crystallinity, as demonstrated
by different techniques. This led to a significant increase in the dissolution rate of praziquantel in
simulated gastrointestinal tract media, except for the praziquantel–montmorillonite product prepared
in dichloromethane, which presented a controlled release in acid medium. Moreover, the drug–clay
interaction products prepared in ethanol were subjected to in vitro cytotoxicity and cell cycle studies.
The interaction product with sepiolite was biocompatible with the HTC116 line cells, and it did not
produce alterations in the cell cycle. However, interaction products with montmorillonite did not
produce cell death, but they altered the cell cycle at the highest concentration tested (20–100
µ
M).
In conclusion, drug–clay interaction products, specifically with sepiolite, showed very promising
results, since they accelerated praziquantel oral release.
Pharmaceutics 2020,12, 1142; doi:10.3390/pharmaceutics12121142 www.mdpi.com/journal/pharmaceutics
Pharmaceutics 2020,12, 1142 2 of 4
Inorganic hydrogels formulated with spring waters and clay minerals are topically applied
to treat musculoskeletal disorders and skin affections. From a pharmaceutical quality perspective,
the safety limits of elemental impurities in clay-based hydrogels were studied by Garc
í
a-Vill
é
n et al. [
3
].
Their results showed that the release of a particular element not only depends on its concentration,
but also on its position in the hydrogel network, concluding that hydrogels prepared with sepiolite,
palygorskite, and local spring water could be topically applied without major intoxication risks.
The wound healing properties of these clay-based hydrogels were addressed using Confocal Laser
Scanning Microscopy to study the morphology of fibroblasts during the wound healing process.
The studied clay-based hydrogels promoted
in vitro
fibroblast motility and, therefore, accelerated
wound healing (Garc
í
a-Vill
é
n et al. [
4
]). The underlying mechanism of action for skin disorders of these
formulations is usually ascribed to the chemical composition of the formulation. Garc
í
a-Vill
é
n et al. [
5
]
assessed the composition and
in vitro
release of elements with potential wound healing effects from
hydrogels prepared with two nanoclays and natural spring water.
In vitro
Franz cell studies were
used and the element concentration was measured by the Inductively Coupled Plasma technique.
Biocompatibility studies were used to evaluate the potential toxicity of the formulation against
fibroblasts. The studied hydrogels released elements with known therapeutic potential in wound
healing. The released ratios of some elements, such as Mg:Ca or Zn:Ca, played a significant role in the
final therapeutic activity of the formulation. In particular, the proliferative activity of fibroblasts was
ascribed to the release of Mn and the Zn:Ca ratio.
Pagano et al. [
6
] intercalated ketoprofen into a lamellar anionic clay ZnAl-hydrotalcite (ZnAl-HTlc),
improving the stability to UV rays and the water solubility of the drug. The hybrid was then formulated
in auto-adhesive patches for local pain treatment. The patches were prepared by a casting method,
starting from a hydrogel based on the biocompatible and bioadhesive polymer NaCMC (Sodium
carboxymethycellulose) and glycerol as a plasticizing agent. The addition of ZnAl-KET in the patch
composition caused an improvement in the mechanical properties of the formulation. Moreover,
a sustained and complete drug release was obtained within 8 h. This allowed reducing the frequency
of anti-inflammatory posology compared to the conventional formulations.
Cirri et al. [
7
] designed fast-dissolving glyburide tablets based on a liquisolid approach using
mesoporous clay (Neusilin
®
US2) or silica (Aeroperl
®
300) and dimethylacetamide or 2-pyrrolidone
as drug solvents, without using the coating materials that are necessary in conventional systems.
The resultant liquisolid tablets provided a marked drug dissolution increase, reaching 98% of dissolved
drug after 60 min, compared to the 40% and 50% obtained from a reference tablet containing the plain
drug and a commercial tablet. The improved glyburide dissolution was attributed to its increased
wetting properties and surface area, due to its amorphization/solubilization within the liquisolid
matrix, as confirmed by DSC and PXRD studies. Mesoporous clay and silica, owing to their excellent
adsorbent, flow, and compressibility properties, avoided the use of coating materials while considerably
improving the liquid-loading capacity, reducing the amount of carrier necessary to obtain freely flowing
powders. Neusilin
®
US2 showed a superior performance with respect to Aeroperl
®
300 regarding the
tablet’s technological properties.
Sandri et al. [
8
] designed and developed electrospun scaffolds, entirely based on biopolymers,
loaded with montmorillonite or halloysite and intended for skin reparation and regeneration.
The scaffolds were manufactured by means of electrospinning and were characterized for their
chemico-physical and preclinical properties. The scaffolds proved to possess the capability to enhance
fibroblast attachment and proliferation with negligible proinflammatory activity. The capability
to facilitate the cell adhesion is probably due to their unique 3D structure, which assists
in cell homing and would facilitate wound healing
in vivo
. Faccendini et al. [
9
] developed
chitosan/glycosaminoglycan-based scaffolds loaded with norfloxacin (free or in montmorillonite
hybrids). All the scaffolds were proven to be degraded via lysozyme (this should ensure scaffold
resorption), and this sustained the drug release (from 50% to 100% in 3 days, depending on system
composition), especially when the drug was loaded in the scaffolds as a clay-based nanocomposite.
Pharmaceutics 2020,12, 1142 3 of 4
Moreover, the scaffolds were able to decrease the bioburden at least 100-fold, proving that drug
loading in the scaffolds did not impair the antimicrobial activity of norfloxacin. Chondroitin sulfate
and montmorillonite in the scaffolds are proven to possess a synergistic performance, enhancing the
fibroblast proliferation without impairing norfloxacin’s antimicrobial properties. The scaffold based
on chondroitin sulfate, containing 1% norfloxacin in the nanocomposite, demonstrated an adequate
stiffness to sustain fibroblast proliferation and the capability to sustain antimicrobial properties to
prevent/treat non-healing wound infections during the healing process.
The publication by Luo et al. [
10
] focused on halloysite nanotubes (HNTs) functionalized with folic
acid to selectively target cancer cells and a fluorochrome to visualize the nanoparticle. The functionalized
HNTs were loaded with methotrexate. and the cell viability, proliferation, and uptake efficiency in colon
cancer, osteosarcoma, and a pre-osteoblast cell line (MC3T3-E1) were evaluated. The functionalized
HNTs showed a high methotrexate loading efficiency and a prolonged release. Moreover, non-cancerous
cells were unaffected after exposure to the formulation. Consequently, the nanoparticle designed
was demonstrated to exclusively target cancer cells, which consequently reduces the methotrexate
side-effects caused by the off-targeting of anti-cancer drugs.
This Special Issue evidences the high potential and versatility of clay minerals in pharmaceutics.
Despite being ingredients whose use dates back to ancient times, they continue to play a crucial role in
the present, both as excipients and actives in a wide variety of dosage forms and novel technological
strategies, such as tissue engineering and targeted cancer treatments.
Conflicts of Interest: The authors declare no conflict of interest.
References
1.
Maestrelli, F.; Cirri, M.; Garc
í
a-Vill
é
n, F.; Borrego-S
á
nchez, A.; Viseras, C.; Mura, P. Tablets of
“Hydrochlorothiazide in Cyclodextrin in Nanoclay”: A New Nanohybrid System with Enhanced Dissolution
Properties. Pharmaceutics 2020,12, 104. [CrossRef] [PubMed]
2.
Borrego-S
á
nchez, A.; S
á
nchez-Espejo, R.; Garc
í
a-Vill
é
n, F.; Viseras, C.; Sainz-D
í
az, C.I. Praziquantel–Clays
as Accelerated Release Systems to Enhance the Low Solubility of the Drug. Pharmaceutics
2020
,12, 914.
[CrossRef] [PubMed]
3.
Garc
í
a-Vill
é
n, F.; S
á
nchez-Espejo, R.; Borrego-S
á
nchez, A.; Cerezo, P.; Perioli, L.; Viseras, C. Safety of
Nanoclay/Spring Water Hydrogels: Assessment and Mobility of Hazardous Elements. Pharmaceutics
2020
,
12, 764. [CrossRef] [PubMed]
4.
Garc
í
a-Vill
é
n, F.; Faccendini, A.; Miele, D.; Ruggeri, M.; S
á
nchez-Espejo, R.; Borrego-S
á
nchez, A.; Cerezo, P.;
Rossi, S.; Viseras, C.; Sandri, G. Wound Healing Activity of Nanoclay/Spring Water Hydrogels. Pharmaceutics
2020,12, 467. [CrossRef] [PubMed]
5.
Garc
í
a-Vill
é
n, F.; S
á
nchez-Espejo, R.; Borrego-S
á
nchez, A.; Cerezo, P.; Cucca, L.; Sandri, G.; Viseras, C.
Correlation between Elemental Composition/Mobility and Skin Cell Proliferation of Fibrous Nanoclay/Spring
Water Hydrogels. Pharmaceutics 2020,12, 891. [CrossRef] [PubMed]
6.
Pagano, C.; Latterini, L.; Di Michele, A.; Luzi, F.; Puglia, D.; Ricci, M.; Viseras, C.; Perioli, L. Polymeric
Bioadhesive Patch Based on Ketoprofen-Hydrotalcite Hybrid for Local Treatments. Pharmaceutics
2020
,12, 733.
[CrossRef] [PubMed]
7.
Cirri, M.; Mura, P.; Valleri, M.; Brunetti, L. Development and Characterization of Liquisolid Tablets Based on
Mesoporous Clays or Silicas for Improving Glyburide Dissolution. Pharmaceutics
2020
,12, 503. [CrossRef]
[PubMed]
8.
Sandri, G.; Faccendini, A.; Longo, M.; Ruggeri, M.; Rossi, S.; Bonferoni, M.C.; Miele, D.; Prina-Mello, A.;
Aguzzi, C.; Viseras, C.; et al. Halloysite- and Montmorillonite-Loaded Scaffolds as Enhancers of Chronic
Wound Healing. Pharmaceutics 2020,12, 179. [CrossRef] [PubMed]
9.
Faccendini, A.; Ruggeri, M.; Miele, D.; Rossi, S.; Bonferoni, M.C.; Aguzzi, C.; Grisoli, P.; Viseras, C.; Vigani, B.;
Sandri, G.; et al. Norfloxacin-Loaded Electrospun Scaffolds: Montmorillonite Nanocomposite vs. Free Drug.
Pharmaceutics 2020,12, 325. [CrossRef] [PubMed]
Pharmaceutics 2020,12, 1142 4 of 4
10.
Luo, Y.; Humayun, A.; Murray, T.A.; Kemp, B.S.; McFarland, A.; Liu, X.; Mills, D.K. Cellular Analysis
and Chemotherapeutic Potential of a Bi-Functionalized Halloysite Nanotube. Pharmaceutics
2020
,12, 962.
[CrossRef] [PubMed]
Publisher’s Note:
MDPI stays neutral with regard to jurisdictional claims in published maps and institutional
affiliations.
©
2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).